The association between obesity and remission is consistent with previous studies that investigated the association between BMI and response to a number of anti-TNF-α agents, including weight-adjusted infliximab treatment10,11 and treatment combining infliximab with either MTX or MTX, sulfasalazine and prednisolone20. Here, TNF is linked to obesity due to melanocortin 4 receptor deficiency.